. Author manuscript; available in PMC: 2018 May 1.

Published in final edited form as: Pharmacol Res. 2017 Jan 25;119:89–98. doi: 10.1016/j.phrs.2017.01.024

Table 3.

Cabozantinib reverses ABCB1-mediated drug resistance in drug selected resistant cells

Treatment	IC₅₀ ± SD^a (μM) (Resistant fold)

	HEK293/pcDNA3.1	HEK293/ABCB1
Paclitaxel	0.063 ± 0.004(1.00) ^b	2.646 ± 0.212(42.12)
+ Cabo 2.5 μM	0.061 ± 0.003(0.96)	2.523 ± 0.232(40.19)
+ Cabo 5 μM	0.062 ± 0.006(0.97)	2.424 ± 0.233(38.47)
+ Verapamil 5 μM	0.062 ± 0.004(0.95)	0.073 ± 0.009 (0.99)^*

Cell survival was determined by MTT assay as described in Material and Methods.

IC₅₀ values are represented as the mean ± standard deviation (SD).

Resistance fold was calculated by the IC₅₀ values for different substrates, and cisplatin of HEK293/pcDNA3.1 cell lines with cabozantinib or fumitremorgin C (FTC), or the resistant cell line HEK293/ABCB1 in the presence or absence of cabozantinib or FTC, divided by the IC₅₀ values for different substrates of HEK293/pcDNA3.1without the reversing agents.

P<0.05, versus the control group.